Sugi Predict

Sugi Predict / Compounds / SCHEMBL19617652

SCHEMBL19617652

SCHEMBL19617652

COC(=O)C1CN(C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.51
▸ NR1H3 Q13133 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ NPC1 O15118 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MMP2 P08253 1/20 0.36
▸ ANPEP P15144 1/20 0.36
▸ SCN5A Q14524 1/20 0.35
▸ SCN3A Q9NY46 1/20 0.35
▸ FKBP1A P62942 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ SCN4A P35499 1/20 0.35
▸ UCHL1 P09936 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29097169 1.00 NR1H2 (0.51) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL31740849 1.00 NR1H2 (0.51) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL13779901 0.91 NR1H2 (0.42) NR1H2NR1H3SMN1; SMN2HSD17B10NPC1
SCHEMBL30401835 0.85 NR1H2 (0.47) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL282661 0.85 NR1H2 (0.54) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL1849268 0.85 NR1H2 (0.54) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL919744 0.85 NR1H2 (0.54) NR1H2NR1H3SMN1; SMN2PTPN1HSD17B10
SCHEMBL7533067 0.84 HSD17B10 (0.48) NR1H2NR1H3SMN1; SMN2HSD17B10NPC1
SCHEMBL6625172 0.84 HSD17B10 (0.48) NR1H2NR1H3SMN1; SMN2HSD17B10NPC1
SCHEMBL1781543 0.84 HSD17B10 (0.48) NR1H2NR1H3SMN1; SMN2HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-18 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3844151-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
EP-4182308-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 — — EP disclosed
WO-2020101736-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-05-22 — — WO disclosed
US-10647715-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-05-12 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
WO-2020047192-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-03-05 — — WO disclosed
US-20190270743-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-09-05 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 NR1H2 508/4885NR1H3 849/4885SMN1; SMN2 3267/4885
US-10647715-B2 KRas G12C inhibitors KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-20190270743-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 NR1H2 508/4885NR1H3 849/4885SMN1; SMN2 3267/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885NR1H3 1479/4885SMN1; SMN2 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.